# Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

> **NCT04056754** · PHASE3 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 268 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Placebo
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04056754
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-16
- **Primary completion:** 2018-03-14
- **Final completion:** 2019-07-16
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056754, "Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04056754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*